{"id":"NCT02760407","sponsor":"R-Pharm International, LLC","briefTitle":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-06","primaryCompletion":"2019-08-02","completion":"2019-11-05","firstPosted":"2016-05-03","resultsPosted":"2021-04-30","lastUpdate":"2023-09-21"},"enrollment":1648,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Olokizumab 64mg q4w","otherNames":[]},{"type":"DRUG","name":"Olokizumab 64mg q2w","otherNames":[]},{"type":"DRUG","name":"Adalimumab 40mg q2w","otherNames":["Humira"]},{"type":"DRUG","name":"Placebo q2w","otherNames":[]}],"arms":[{"label":"Arm 1: Olokizumab q4w","type":"EXPERIMENTAL"},{"label":"Arm 2: Olokizumab q2w","type":"EXPERIMENTAL"},{"label":"Arm 3: Adalimumab q2w","type":"ACTIVE_COMPARATOR"},{"label":"Arm 4: Placebo q2w","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate (MTX).\n\nThe primary objective of this study was to evaluate the efficacy of OKZ 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active RA inadequately controlled by MTX therapy.\n\nThe secondary objective was to evaluate the efficacy of OKZ relative to adalimumab in subjects with moderately to severely active RA inadequately controlled by MTX therapy.","primaryOutcome":{"measure":"Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response","timeFrame":"at Week 12","effectByArm":[{"arm":"Arm 1: Olokizumab q4w + Methotrexate","deltaMin":342,"sd":null},{"arm":"Arm 2: Olokizumab q2w + Methotrexate","deltaMin":326,"sd":null},{"arm":"Arm 3: Adalimumab q2w + Methotrexate","deltaMin":309,"sd":null},{"arm":"Arm 4: Placebo q2w + Methotrexate","deltaMin":108,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":30},"locations":{"siteCount":203,"countries":["United States","Argentina","Brazil","Bulgaria","Colombia","Czechia","Estonia","Germany","Hungary","Latvia","Lithuania","Mexico","Poland","Romania","Russia","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["36001712"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":477},"commonTop":["Alanine aminotransferase increased","Nasopharyngitis","Upper respiratory tract infection","Hypertension","Hypercholesterolaemia"]}}